Technology ID
TAB-4900
Development of a Self-Amplifying mRNA Zika Vaccine: Merging GSK's mRNA Delivery Vector System with VRC's Zika Proteins
E-Numbers
E-086-2018-0
Lead Inventor
Sharma, Mayuri
Lead IC
NIAID
Co-Inventors
Graham, Barney
Dowd, Kimberly
Ko, Sung-Youl
Pierson, Theodore
Mascola, John
Kong, Wing-pui
Yu, Dong
ICs
NIAID
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Stages
Pre-clinical (in vivo)
The inventors have developed an RNA Zika vaccine construct using the self-amplifying mRNA (SAM®) vaccine platform. This technology combines the GSK SAM mRNA delivery vector system with the VRC’s Zika proteins to optimize immune responses against Zika virus, with the ultimate goal of preventing infection. The vaccine is designed to elicit strong and durable immune responses, potentially offering a promising approach to combat Zika virus disease. The current development stage of this technology is likely in the pre-clinical or early clinical stages of testing.
Commercial Applications
The RNA Zika vaccine construct based on the SAM® vaccine platform has the potential for widespread application in both endemic regions and areas at risk of Zika virus outbreaks. If successful, this vaccine could significantly reduce the burden of Zika virus disease, particularly in pregnant women and their offspring who are most at risk of complications. Furthermore, the adaptability of the SAM® platform could enable rapid development and deployment of vaccines against other emerging infectious diseases, providing a valuable tool for global health security.
Competitive Advantages
The RNA Zika vaccine construct based on the self-amplifying mRNA (SAM®) vaccine platform offers a potent and targeted approach to combating Zika virus. By combining the GSK SAM mRNA delivery vector system with the VRC’s Zika proteins, the vaccine aims to elicit strong and long-lasting immune responses. This technology not only has the potential to prevent Zika virus infection but also demonstrates versatility for addressing other infectious diseases. Its scalability, safety profile, and potential for enhanced immune responses position it as a promising candidate in the field of vaccine development.
Licensing Contact: